2021-2030 Analysis and Review Human Tetanus Immunoglobulin Market
Human Tetanus Immunoglobulin Market by Demography (Adult and Children), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027
The human tetanus immunoglobulin market was valued at USD 1,061.0 Mn by 2019. Rising prevalence of tetanus prone injuries worldwide primarily drives the human tetanus immunoglobulin market growth. Furthermore, the provision of free and compulsory immunization of children and increasing public health awareness together accentuate the market growth.
Human tetanus immunoglobulin mainly comprises of immunoglobulin in which the concentration of specific IgG to tetanus toxin is close to 100 IU/ml in nominal 250 IU vials. It serves as immediate prophylaxis in patients who have acquired tetanus prone injuries and whose previous immunization is not clear. Furthermore, it is also widely employed in patients showing deficiency in antibody production or vaccinated patients having high-risk wounds.
The major segments related to the human tetanus immunoglobulin market are:
By Demography (2017–2027; US$ Mn)
Adult
Children
By Distribution Channel (2017–2027; US$ Mn)
Hospital Pharmacy
Retail Pharmacy
Others
Geography Segment (2017–2027; US$ Mn)
North America
U.S.
Canada
Europe
United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe
Asia Pacific
China
Japan
Rest of Asia Pacific
Latin America (LATAM)
Brazil
Mexico
Rest of Latin America
Middle East and Africa (MEA)
GCC
Rest of MEA
Justification for study?
Report gist?
The study includes the profiles of major market players with a significant global and regional presence along with top company positioning.
Significant customers?
Segment Analysis
Children are spearheading the demography segment for the human tetanus immunoglobulin market. Increasing public health awareness regarding the future benefits of prophylactic immunization and proactive role adopted by the government healthcare agencies in providing free immunization of human tetanus immunoglobulin to children across the globe together drive the market growth. Adult demography will be showcasing comfortable market growth during the forecast period owing to the growing incidence of tetanus infection among individuals working in cattle and dairy industries and compulsory immunization of researchers engaged in performing preclinical trials of new drug entity.
Hospital pharmacy is representing the largest market share in the distribution channel segment for the human tetanus immunoglobulin market. Increasing public health awareness regarding the compulsory immunization programs adopted by the government health agencies in the primary healthcare centers worldwide makes it imperative for precise compounding of the human tetanus immunoglobulin under the supervision of hospital pharmacists. Retail pharmacy is expected to cater to exemplary market performance in the near future on account of its ability to provide medical aid to people residing in remote locations.
The Asia Pacific is currently dominating the geography segment for the human tetanus immunoglobulin market. The growing incidence of tetanus infection among the adult population primarily drives the market growth in the region. As per the latest research citings presented by the World Health Organization (WHO), approximately 45% of the deaths in the neonates were associated with tetanus infection in the South Asia region. Proactive role adopted by the government healthcare agencies for the compulsory immunization of children to prevent future tetanus infection further accentuates the market growth in the region. North Africa is the global hotspot for tetanus infection, hence it presents a lucrative market opportunity for western giants to establish retail outlets and subsidiaries in the region. Additionally, the free medical aid and immunization program conducted by the Red Cross, United Nations, etc., in the sub-Saharan regions further increases the demand for human tetanus immunoglobulin. Europe is considered as the second-largest regional segment for human tetanus immunoglobulin on account of the domicile of key players such as Octapharma AG., Grifols SA., Kedrion S.p.A., CSL Behring, etc. Latin America is anticipated to be the fastest-growing regional segment for the human tetanus immunoglobulin market due to the rising prevalence of tetanus infection in the Amazon basin and developing healthcare infrastructure.
$4,600 | |
$6,600 | |
$13,200 |
Request customization |
Get market alerts |
Ask for regional data |
Ask for country-specific data |